Anti-Mouse CD8 (YTS-169) In Vivo Antibody - Low Endotoxin

Cao, Y. et al. Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation. J Nanobiotechnol, 2023, 21, 404.

Mouse

CD8

>1mg/ml

Rat IgG2b

Rat

Anti-CD8 In Vivo Antibody - Ultra Low Endotoxin [YTS-169] (ICH1043UL)

Bulk Anti-Human CD8 (UCHT-4) Antibody (ICH1005), Anti-Mouse CD8a (53-6.7) In Vivo Antibody - Low Endotoxin (ICH1044), Anti-Mouse CD8a (2.43) In Vivo Antibody - Low Endotoxin (ICH1045), Anti-Mouse CD8 (116-13.1) In Vivo Antibody - Low Endotoxin (ICH1249)

Aggregation level ≤ 5%

CBA mouse thymocytes

Present on the surface of most thymocytes and a subpopulation of mature T-lymphocytes which include most T suppressor/cytotoxic cells. CD8 participates in T-cell activation through its association with the T-cell receptor complex and protein tyrosine kina

ICH3001-100ml ICH3002-100ml ICH3003-100ml

P01731

Blue ice

ICH1043 is a purified rat anti-mouse CD8 monoclonal antibody, clone YTS-169, of the rat IgG2b isotype. YTS-169 recognises mouse CD8 (CD8 alpha) and is a widely used reagent for the in vivo depletion of CD8-positive cytotoxic T lymphocytes, making it well suited to functional studies that dissect the contribution of CD8 T cells to anti-tumour immunity, infection, autoimmunity and transplant responses. The clone is also validated for flow cytometry and IHC on frozen sections, allowing depletion efficiency to be confirmed on the same material. This preparation is manufactured to support in vivo work: it is supplied at low endotoxin levels (research-grade less than 1 EU/mg; ultra-low options less than 0.5 EU/mg) to minimise confounding innate immune activation, is available in bulk milligram-to-gram quantities suitable for repeat-dosing cohort studies, and is provided for research use only. Because researchers typically search by clone, note that YTS-169 is frequently paired with the non-depleting or complementary anti-CD4 clones in T-cell subset depletion experiments. CD8 is a cell-surface glycoprotein that serves as the co-receptor for the T-cell receptor (TCR) on major histocompatibility complex (MHC) class I-restricted T lymphocytes. It is expressed predominantly as an alpha-beta heterodimer on cytotoxic T cells, with an alpha-alpha homodimer form on some dendritic and other cells. During antigen recognition, the CD8 alpha chain binds the conserved alpha-3 domain of MHC class I, stabilising the TCR-peptide-MHC interaction and recruiting the tyrosine kinase Lck to the intracellular signalling complex, thereby lowering the threshold for T-cell activation. CD8-positive cytotoxic T lymphocytes are central effectors of adaptive immunity, killing virally infected, intracellular-pathogen-infected and tumour cells through perforin/granzyme release and Fas-mediated pathways, and are a principal target of many cancer immunotherapies. The clone here targets the CD8 alpha chain.

T-cell surface glycoprotein Lyt-2, T-cell surface glycoprotein CD8 alpha chain, Cd8a, Lyt-2, YTS 169, YTS169

YTS-169

Anti-CD8 In Vivo Antibody - Low Endotoxin (YTS-169) recognizes an epitope on Mouse CD8

This monoclonal antibody was purified using Protein G

0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added.

anti-CD8 In Vivo Antibody - Low Endotoxin (YTS-169) is stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

IHC (Frozen), In vivo Depletion, Flow Cytometry

Immunohistochemistry on Frozen Sections: This antibody should give satisfactory staining results when used on frozen sections but the concentration is assay dependent. Each investigator should determine their own optimal working dilution for specific applications.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.